1. Kamada Y, Fujii H, Suzuki Y, et al. Clinical characteristics of steatotic liver disease categories in a large cohort of Japanese health checkup participants. Gastro Hep Adv 2024; 3: 1148-1156.
2.
Suzuki K, Tamaki N, Kurosaki M, et al. Concordance between metabolic dysfunction-associated steatotic liver disease and nonalcoholic fatty liver disease. Hepatol Res 2024; 54: 600-605.
3.
Nakano M, Yatsuhashi H, Bekki S, et al. Trends in hepatocellular carcinoma incident cases in Japan between 1996 and 2019. Sci Rep 2022; 12: 1517.
4.
Rumgay H, Arnold M, Ferlay J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol 2022; 77: 1598-1606.
5.
Villanueva A. Hepatocellular carcinoma. N Engl J Med 2019; 380: 1450-1462.
6.
Ishiguro S, Inoue M, Tanaka Y, et al. Serum aminotransferase level and the risk of hepatocellular carcinoma: a population-based cohort study in Japan. Eur J Cancer Prev 2009; 18: 26-32.
7.
Younossi ZM, Golabi P, de Avila L, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis. J Hepatol 2019; 71: 793-801.
8.
Francque SM, Marchesini G, Kautz A, et al. Non-alcoholic fatty liver disease: A patient guideline. JHEP Rep 2021; 3: 100322.
9.
Ishiba H, Sumida Y, Tanaka S, et al. The novel cutoff points for the FIB4 index categorized by age increase the diagnostic accuracy in NAFLD: a multi-center study. J Gastroenterol 2018;
10.
53: 1216-1224.
11.
Kariyama K, Kawanaka M, Nouso K, et al. Fibrosis-3 Index: A new score to predict liver fibrosis in patients with nonalcoholic fatty liver disease without age as a factor. Gastro Hep Adv 2022; 1: 1108-1113.
12.
Johnson PJ, Berhane S, Kagebayashi C, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach – the ALBI grade. J Clin Oncol 2015; 33: 550-558.
13.
Pugh RN, Murray-Lyon IM, Dawson JL, et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646-649.
14.
Abe M, Miyake T, Kuno A, et al. Association between Wisteria floribunda agglutinin-positive Mac-2 binding protein and the fibrosis stage of non-alcoholic fatty liver disease. J Gastroenterol 2015; 50: 776-784.
15.
Ishikawa T, Kodama E, Kobayashi T, et al. Clinical efficacy of Mac-2-binding protein glycosylation isomer as a biomarker for albumin-bilirubin grade and the Controlling Nutritional Status score in chronic liver disease: investigation of cut-off values by the type of chronic liver disease. Ann Palliat Med 2022; 11: 2658-2667.
16.
Ishikawa T, Imai M, Endo S, et al. Clinical efficacy of an SGLT2 inhibitor in type 2 diabetes complicated by nonalcoholic fatty liver disease and changes in body composition. Gut Gastroenterol 2020; 3: 1-6.
17.
Ishikawa T, Terai N, Sato R, et al. Clinical efficacy and body composition changes with sodium glucose cotransporter 2 inhibitor/glucagon-like peptide-1 antagonist combination therapy in patients with type 2 diabetes mellitus-associated nonalcoholic fatty liver disease. Intern Med 2024; 63: 2491-2497.
18.
Tokushige K, Ikejima K, Ono M, et al. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020. J Gastroenterol 2021; 56: 951-963.
19.
Yamaguchi K, Yang L, McCall S, et al. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology 2007; 45: 1366-1374.
20.
Crook MA, Lynas J, Wray R. A paradoxical severe decrease in serum HDL-cholesterol after treatment with a fibrate. J Clin Pathol 2000; 53: 796-797.
21.
Targher G, Byrne CD, Tilg H. MASLD: A systemic metabolic disorder with cardiovascular and malignant complications. Gut 2024; 73: 691-702.
22.
Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008; 40: 1461-1465.
23.
Salameh H, Hanayneh MA, Masadeh M, et al. PNPLA3 as a genetic determinant of risk for and severity of non-alcoholic fatty liver disease spectrum. J Clin Transl Hepatol 2016; 4: 175-191.
24.
Unalp-Arida A, Ruhl CE. Patatin-like phospholipase domain-containing protein 3 I148M and liver fat and fibrosis scores predict liver disease mortality in the U.S. population. Hepatology 2020; 71: 820-834.
25.
Toffoli B, Comar C, Grillo A, et al. PNPLA3 polymorphism is inversely correlated with aortic stiffness in patients with metabolic dysfunction-associated steatotic liver disease without fibrosis. Int J Mol Sci 2025; 26: 3256.
26.
Marigorta UM, Millet O, Lu SC, Mato JM. Dysfunctional VLDL metabolism in MASLD. NPJ Metab Health Dis 2024; 2: 16.
27.
Arvind A, Henson JB, Osganian SA, et al. Risk of cardiovascular disease in individuals with nonobese nonalcoholic fatty liver disease. Hepatol Commun 2022; 6: 309-319.
28.
Martínez-Arranz I, Bruzzone C, Noureddin M, et al. Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles. Hepatology 2022; 76: 1121-1134.
29.
Austin MA. Plasma triglyceride and coronary heart disease.
30.
Arterioscler Thromb 1991; 11: 2-14.
31.
Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007; 298: 299-308.
32.
Nordestgaard BG. Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: New insights from epidemiology, genetics, and biology. Circ Res 2016; 118: 547-563.
33.
Sarwar N, Danesh J, Eiriksdottir G, et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation 2007; 115: 450-458.
34.
Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999; 341: 410-418.
35.
Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial [published correction appears in Lancet. 2006 Oct 21;368(9545):1420] [published correction appears in Lancet. 2006 Oct 21;368(9545):1415]. Lancet 2005; 366: 1849-1861.
36.
Davis TM, Ting R, Best JD, et al. Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. Diabetologia 2011; 54: 280-290.
37.
Mychaleckyj JC, Craven T, Nayak U, et al. Reversibility of fenofibrate therapy-induced renal function impairment in ACCORD type 2 diabetic participants. Diabetes Care 2012; 35: 1008-1014.
38.
Sobukawa Y, Hatta T, Funaki D, Nakatani E. Safety of combined statin and fibrate therapy: risks of liver injury and acute kidney injury in a cohort study from the Shizuoka Kokuho database. Drugs Real World Outcomes 2024; 11: 317-330.
39.
Fruchart JC, Santos RD, Aguilar-Salinas C, et al. The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential: A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation. Cardiovasc Diabetol 2019; 18: 71.
40.
Yamashita S, Masuda D, Matsuzawa Y. Pemafibrate, a new selective PPARα modulator: Drug concept and its clinical applications for dyslipidemia and metabolic diseases. Curr Atheroscler Rep 2020; 22: 5.
41.
Kim K, Ginsberg HN, Choi SH. New, novel lipid-lowering agents for reducing cardiovascular risk: beyond statins. Diabetes Metab J 2022; 46: 817-818.
42.
Sasaki Y, Asahiyama M, Tanaka T, et al. Pemafibrate, a selective PPARα modulator, prevents non-alcoholic steatohepatitis development without reducing the hepatic triglyceride content. Sci Rep 2020; 10: 7818.
43.
Seko Y, Yamaguchi K, Umemura A, et al. Effect of pemafibrate on fatty acid levels and liver enzymes in non-alcoholic fatty liver disease patients with dyslipidemia: A single-arm, pilot study. Hepatol Res 2020; 50: 1328-1336.
44.
Shinozaki S, Tahara T, Lefor AK, Ogura M. Pemafibrate decreases markers of hepatic inflammation in patients with non-alcoholic fatty liver disease. Clin Exp Hepatol 2020; 6: 270-274.
45.
Hatanaka T, Kakizaki S, Saito N, et al. Impact of pemafibrate in patients with hypertriglyceridemia and metabolic dysfunction-associated fatty liver disease pathologically diagnosed with non-alcoholic steatohepatitis: A retrospective, single-arm study. Intern Med 2021; 60: 2167-2174.
46.
Shinozaki S, Tahara T, Lefor AK, Ogura M. Pemafibrate improves hepatic inflammation, function and fibrosis in patients with non-alcoholic fatty liver disease: a one-year observational study. Clin Exp Hepatol 2021; 7: 172-177.
47.
Nakajima A, Eguchi Y, Yoneda M, et al. Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferatoractivated receptor α modulator (SPPARMα), versus placebo in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2021; 54: 1263-1277.
48.
Morishita A, Oura K, Takuma K, et al. Pemafibrate improves liver dysfunction and non-invasive surrogates for liver fibrosis in patients with non-alcoholic fatty liver disease with hypertriglyceridemia: a multicenter study. Hepatol Int 2023; 17: 606-614.
49.
Shinozaki S, Tahara T, Miura K, et al. Pemafibrate therapy for non-alcoholic fatty liver disease is more effective in lean patients than obese patients. Clin Exp Hepatol 2022; 8: 278-283.
50.
Kikuchi M, Kikuchi M, Konishi M. Usefulness of pemafibrate for non-alcoholic fatty liver disease with hypertriglyceridemia. Clin Exp Hepatol 2024; 10: 182-187.
51.
Ishikawa T, Terai N, Igarashi T, et al. Effects of body composition and liver function after long-term pemafibrate treatment on dyslipidemia-associated non-alcoholic fatty liver disease. Clin Exp Hepatol 2023; 9: 172-178.
52.
Das Pradhan A, Glynn RJ, Fruchart JC, et al. Triglyceride lowering with pemafibrate to reduce cardiovascular risk. N Engl J Med 2022; 387: 1923-1934.
Copyright: © Clinical and Experimental Hepatology. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0). License (http://creativecommons.org/licenses/by-nc-sa/4.0/) enables reusers to distribute, remix, adapt, and build upon the material in any medium or format for noncommercial purposes only, and only so long as attribution is given to the creator. If you remix, adapt, or build upon the material, you must license the modified material under identical terms.
